SLU-PP-332 vs Trenbolone
Emerging vs Moderate Research
avoid Mechanism-based · 53% Both SLU-PP-332 and Trenbolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
SLU-PP-332 Trenbolone
Weight 290.32 Da 270.37 Da (base)
Half-life Under investigation (no human PK data) ~3 days (acetate)
Chain Non-peptide small molecule —
Type Synthetic ERR agonist 19-nortestosterone derivative (C18H22O2), trienone steroid
Key Benefits
SLU-PP-332
01 Exercise mimetic effects without physical activity
02 12% weight loss in 28 days
03 70% increased endurance
04 25% enhanced fatty acid oxidation
05 Improved insulin sensitivity
06 Reduced hepatic steatosis
07 Cardiac protection
08 Reversal of age-related mitochondrial dysfunction
Trenbolone
01 Exceptional lean muscle mass accrual with minimal water retention due to non-aromatizing profile
02 Dramatic body recomposition capability -- simultaneous muscle gain and fat loss even in caloric deficit
03 Approximately five times the anabolic and androgenic potency of testosterone (500:500 ratio)
04 Powerful anti-catabolic effects through glucocorticoid receptor antagonism, protecting muscle during dieting
05 Significant increases in strength across all compound movements, often rapid in onset
06 Enhanced nutrient partitioning, directing calories toward lean tissue accretion over fat storage
07 Pronounced muscle hardness, density, and vascularity due to absence of estrogenic water retention
08 Increased IGF-1 production in muscle tissue, amplifying growth signaling pathways
Dosing Protocols
SLU-PP-332
NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP) / Research only - not approved for human use
Standard Metabolic Protocol 50 mg/kg (animal dosing) Twice daily
Acute Exercise Enhancement 50 mg/kg (animal dosing) Single dose 1 hour pre-exercise
Extended Treatment 50 mg/kg (animal dosing) Twice daily for 4-8 weeks
Trenbolone
200-400 mg/week / Every other day (acetate) or 2x per week (enanthate)
Recomposition - Moderate (Acetate) 200-300 mg/week (50-75 mg every other day) Every other day
Advanced Cutting (Acetate) 300-400 mg/week (75-100 mg every other day) Every other day
Lean Bulk (Enanthate) 200-400 mg/week 2x per week
Contest Preparation - Advanced 300-500 mg/week Every other day (acetate) or 2x per week (enanthate)
Side Effects
SLU-PP-332
Animal studies show favorable safety with no severe effects at therapeutic doses
Well-tolerated in rodents and canines
No liver, kidney, or cardiac toxicity documented
No lean mass loss
Does not suppress hormones or act as stimulant
Minor plasma cholesterol and liver enzyme changes in some studies
Trenbolone
Insomnia and severely disrupted sleep architecture (one of the most universally reported side effects, affecting the majority of users)
Night sweats, often drenching, requiring sheet changes
Significantly reduced cardiovascular endurance and aerobic capacity
Increased aggression, irritability, and shortened temper
Anxiety and restlessness, particularly at higher doses
Tren cough: acute, intense coughing fit lasting 30-90 seconds immediately after injection, caused by a small amount of oil entering a blood vessel
Dark-colored urine (oxidized metabolites; not necessarily indicative of kidney damage but should be monitored)
Elevated body temperature and increased sweating throughout the day
Acne and oily skin, particularly on shoulders, back, and chest
Accelerated hair loss in those genetically predisposed to male pattern baldness
Profoundly suppressive of natural testosterone production (near-complete HPT axis shutdown)
Increased heart rate and elevated blood pressure
Contraindications
NOT FOR HUMAN USE - no approved human dose
No human clinical trials conducted
Potential interaction with diabetes medications
First steroid cycle or limited anabolic steroid experience (trenbolone is strictly an advanced-only compound)
Pre-existing cardiovascular disease, cardiomyopathy, or significant cardiac risk factors
History of mental health conditions: anxiety disorders, depression, bipolar disorder, or psychotic episodes
Liver disease or significantly elevated liver enzymes
Kidney disease or impaired renal function
Uncontrolled hypertension
Polycythemia (hematocrit above 54% at baseline)
Prostate cancer or history of hormone-sensitive cancers
Active or recent substance abuse (trenbolone's psychological effects can exacerbate addictive behaviors)
Pregnancy or potential for pregnancy in female partners (extremely virilizing compound)
Research Evidence
SLU-PP-332 Trenbolone
Status Emerging Moderate Research
References 4 studies 5 studies
Latest 2025 January 2023
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.